Assaad Marc, Shamsi Wasif, Loschner Anthony, Del Mar Cirino-Marcano Maria
Section of Pulmonary, Critical Care and Sleep Medicine Carilion Clinic, Virginia Tech School of Medicine, USA.
Respir Med Case Rep. 2024 Dec 12;53:102151. doi: 10.1016/j.rmcr.2024.102151. eCollection 2025.
Chronic obstructive lung disease is the third leading cause of death worldwide. It affects the airways and lung parenchyma leading to emphysema. Bronchoscopic lung volume reduction is another strategy that aims to reduce air trapping and hyperinflation, leading to improvement in symptoms and pulmonary function. Several techniques have been employed, one of them is the blocking method using Zephyr or Spiration valves. The use of both valves is approved by the Food and Drug Administration view their established efficacy in improving lung functions, quality of life and survival. Although they have a relatively safe profile, several adverse events have been reported, pneumothorax being the most common and pleural effusion being the least reported. We show herein, a case of 74-year-old female presenting with pleural effusion secondary to bronchoscopic lung volume reduction. Although uncommon, highlighting this potential outcome is crucial.
慢性阻塞性肺疾病是全球第三大致死原因。它会影响气道和肺实质,导致肺气肿。支气管镜下肺减容术是另一种旨在减少气体潴留和肺过度充气的治疗策略,可改善症状和肺功能。目前已采用了多种技术,其中之一是使用Zephyr或Spiration瓣膜的封堵法。鉴于这两种瓣膜在改善肺功能、生活质量和生存率方面已证实的疗效,美国食品药品监督管理局已批准其使用。尽管它们的安全性相对较高,但仍有一些不良事件的报道,气胸最为常见,而胸腔积液的报道最少。我们在此展示了一例74岁女性因支气管镜下肺减容术继发胸腔积液的病例。尽管这种情况并不常见,但强调这一潜在结果至关重要。